Abstract：
Drug-induced liver injury (DILI) is an adverse reaction to drugs and their metabolites. The activation of adaptive immune and inflammatory responses plays an important role in the pathogenesis of DILI. Glucocorticoids (GCs) have powerful anti-inflammatory and immunosuppressive effects and have been used to treat a variety of immune-mediated liver diseases. Due to the important role of the immune system in DILI, GCs are widely used in the clinical treatment of DILI; however, whether they are beneficial to patients remains controversial. There is no uniform standard for the timing, dosage, and population selection of GCs, which mainly depend on the clinician\'s experience. Therefore, elucidating whether GCs are beneficial for patients with DILI is an urgent clinical problem. Our review summarizes the recent literature and discusses the clinical efficacy, applicable population, application timing, and efficacy of GCs in special types of DILI, providing a reference for the clinical application of GCs.
摘要：
药物性肝损伤(DILI)是药物及其代谢产物的不良反应。适应性免疫和炎症反应的激活在DILI的发病机制中起重要作用。糖皮质激素（GC）具有强大的抗炎和免疫抑制作用，已用于治疗多种免疫介导的肝脏疾病。由于免疫系统在DILI中的重要作用，GCs广泛用于DILI的临床治疗；然而，它们是否对患者有益仍然存在争议。时间没有统一的标准,剂量,和GCs的种群选择，这主要取决于临床医生的经验。因此,阐明GCs是否对DILI患者有益是一个紧迫的临床问题.我们的综述总结了最近的文献，并讨论了临床疗效，适用人群,应用程序定时，GCs在特殊类型的DILI中的功效，为GCs的临床应用提供参考。
